Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Precision Platform Study of Refractory Triple-negative Breast Cancer Based on Molecular Subtyping (A Phase II, Open-label, Single-center Platform Study

Next Previous
Trial Profile

Precision Platform Study of Refractory Triple-negative Breast Cancer Based on Molecular Subtyping (A Phase II, Open-label, Single-center Platform Study

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 24 Apr 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Most Recent Events

  • 16 Apr 2026 Number of treatment arms are increased from 8 to 9 by the addition of "Experimental: All-Comer/TQB2102 plus TQB2868".
  • 02 Apr 2026 Drug "Drug: E2: SHR-A1811 with everolimus" has been added in combination with Drug: E1: SHR-A1811 in the Experimental arm "LAR / HER2-low".
  • 02 Apr 2026 Planned End Date changed from 1 Jun 2026 to 31 Dec 2028.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top